In Search of Advanced Tumor Diagnostics and Treatment: Achievements and Perspectives of Carbonic Anhydrase IX Targeted Delivery
- 6 May 2020
- journal article
- review article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 17 (6) , 1800-1815
Abstract
The research of how cells sense and adapt the oxygen deficiency has been recognized as worth winning a Nobel Prize in 2019. Understanding hypoxia-driven molecular machinery paved a path for novel strategies in fighting hypoxia-related diseases including cancer. The oxygen depletion inside the tumor provokes HIF-1 dependent gene and proteins expression which helps the tumor to survive. For this reason, tumor related molecules are in the spotlight for scientists developing anticancer agents. One of such targets is carbonic anhydrase IX (CA IX) - a protein located on the outer cell membrane of most hypoxic tumor cells. This offers the opportunity to exploit it as a target for delivery of cytotoxic drugs, dyes or radioisotopes to the cancer cells. Therefore, researchers investigate CA IX specific small molecules and antibodies as the tumor-targeting moieties in nanosystems and conjugates which are expected to overcome the limitations of some existing diagnostic and treatment strategies. This review covers the vast majority of CA IX-targeted systems (nanoparticle and conjugate based) for both therapeutic and imaging purposes published up to now. Furthermore, it shows their stage of development and gives an assessment of their clinical translation possibilities.Keywords
This publication has 107 references indexed in Scilit:
- Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell CarcinomaInternational Journal of Molecular Sciences, 2013
- Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization LaboratoryIntegrative Biology, 2012
- To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug deliveryJournal of Controlled Release, 2010
- Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1α, GLUT1, and CAIXVirchows Archiv, 2010
- Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancerTrends in Pharmacological Sciences, 2009
- Carbonic Anhydrase Inhibitor Coated Gold Nanoparticles Selectively Inhibit the Tumor-Associated Isoform IX over the Cytosolic Isozymes I and IIJournal of the American Chemical Society, 2008
- Hypoxia activates the capacity of tumor‐associated carbonic anhydrase IX to acidify extracellular pHFEBS Letters, 2004
- Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IXJournal of Immunological Methods, 2003
- Glivec (STI571, imatinib), a rationally developed, targeted anticancer drugNature Reviews Drug Discovery, 2002
- Targeting Hyperthermia for Renal Cell Carcinoma Using Human MN Antigenspecific MagnetoliposomesJapanese Journal of Cancer Research, 2001